Lubazodone

Lubazodone
Clinical data
Other names	YM-992; YM-35995
Routes of; administration	Oral
ATC code	None;
Identifiers
	IUPAC name (2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine;
JSmol)	Interactive image;
	SMILES C1CC2=C(C=CC(=C2C1)F)OC[C@@H]3CNCCO3;
	InChI InChI=1S/C14H18FNO2/c15-13-4-5-14(12-3-1-2-11(12)13)18-9-10-8-16-6-7-17-10/h4-5,10,16H,1-3,6-9H2/t10-/m0/s1 ; Key:HTODIQZHVCHVGM-JTQLQIEISA-N ;
	(what is this?) (verify)

Lubazodone (developmental code names YM-992, YM-35995) is an experimental

affinities being for the α₁-adrenergic receptor (K_i = 200 nM) and the 5-HT_2C receptor (K_i = 680 nM).^[1] Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT_2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI.^[1]^[2] It reached phase II clinical trials for depression,^[3] but development was discontinued in 2001 reportedly due to the "erosion of the SSRI market in the United States".^[1]

References

^
PMID 17017959
.

^
ISBN 978-1-84973-494-3
.

^ ^a ^b "Lubazodone". AdisInsight. Springer Nature Switzerland AG.

External links

Lubazodone - AdisInsight

[pmid17017959-1] 
PMID 17017959
.

[RankovicHargreaves2012-2] 
ISBN 978-1-84973-494-3
.

[AdisInsight-3] "Lubazodone". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]

[3]